Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics

Amicus Therapeutics, Inc. (FOLD)

Today's Latest Price: $23.18 USD

1.30 (5.94%)

Updated Dec 4 4:00pm

Add FOLD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

FOLD Stock Summary

  • FOLD's price/sales ratio is 24.65; that's higher than the P/S ratio of 92.56% of US stocks.
  • With a year-over-year growth in debt of 114.6%, Amicus Therapeutics Inc's debt growth rate surpasses 89.35% of about US stocks.
  • Revenue growth over the past 12 months for Amicus Therapeutics Inc comes in at 53.9%, a number that bests 90.35% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FOLD, based on their financial statements, market capitalization, and price volatility, are PTCT, FPRX, RMBS, XLRN, and MGEN.
  • Visit FOLD's SEC page to see the company's official filings. To visit the company's web site, go to

FOLD Stock Price Chart Interactive Chart >

Price chart for FOLD

FOLD Price/Volume Stats

Current price $23.18 52-week high $23.60
Prev. close $21.88 52-week low $6.25
Day low $22.00 Volume 3,119,100
Day high $23.33 Avg. volume 2,774,791
50-day MA $18.88 Dividend yield N/A
200-day MA $14.16 Market Cap 6.04B

Amicus Therapeutics, Inc. (FOLD) Company Bio

Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.

FOLD Latest News Stream

Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream

Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about Amicus Therapeutics Inc that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

Amicus Therapeutics (FOLD) Investor Presentation - Slideshow

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Amicus Therapeutics EPS beats by $0.07, beats on revenue

Amicus Therapeutics (FOLD): Q2 GAAP EPS of -$0.20 beats by $0.07.Revenue of $62.35M (+41.3% Y/Y) beats by $0.08M.Press Release...

Seeking Alpha | August 10, 2020

Recap: Amicus Therapeutics Q2 Earnings

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share …

Benzinga | August 10, 2020

Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript | The Motley Fool

FOLD earnings call for the period ending June 30, 2020.

The Motley Fool | August 10, 2020

New Strong Sell Stocks for July 31st

Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

Yahoo | July 31, 2020

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo 11.76%
3-mo 70.32%
6-mo 79.83%
1-year 131.34%
3-year 85.29%
5-year 120.13%
YTD 137.99%
2019 1.67%
2018 -33.43%
2017 189.54%
2016 -48.76%
2015 16.59%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8474 seconds.